212890-86-3

Basic information

• Product Name: 1-Pyrrolidinecarboxylic acid, 2-(hydroxyMethyl)-4,4-diMethyl-, 1,1-diMethylethyl ester, (2S)-
• Synonyms: 1-Pyrrolidinecarboxylic acid, 2-(hydroxyMethyl)-4,4-diMethyl-, 1,1-diMethylethyl ester, (2S)-;(S)-tert-butyl 2-(hydroxymethyl)-4,4-dimethylpyrrolidine-1-carboxylate;tert-butyl (2S)-2-(hydroxymethyl)-4,4-dimethylpyrrolidine-1-carboxylate;tert-butyl (S)-2-(hydroxymethyl)-4,4- dimethylpyrrolidine-1-carboxylate
• CAS NO: 212890-86-3
• Molecular Formula: C₁₂H₂₃NO₃
• Molecular Weight: 229.31592
• EINECS: -0
• Mol File: 212890-86-3.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 303.9±15.0 °C(Predicted)
• Appearance: /
• Density: 1.024±0.06 g/cm3(Predicted)
• PKA: 14.77±0.10(Predicted)
• CAS DataBase Reference: 1-Pyrrolidinecarboxylic acid, 2-(hydroxyMethyl)-4,4-diMethyl-, 1,1-diMethylethyl ester, (2S)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Pyrrolidinecarboxylic acid, 2-(hydroxyMethyl)-4,4-diMethyl-, 1,1-diMethylethyl ester, (2S)-(212890-86-3)
• EPA Substance Registry System: 1-Pyrrolidinecarboxylic acid, 2-(hydroxyMethyl)-4,4-diMethyl-, 1,1-diMethylethyl ester, (2S)-(212890-86-3)

Safety Data

• Hazardous Substances Data: 212890-86-3(Hazardous Substances Data)

Usage

General Description

The chemical "1-Pyrrolidinecarboxylic acid, 2-(hydroxyMethyl)-4,4-diMethyl-, 1,1-diMethylethyl ester, (2S)-" is a compound that belongs to the class of pyrrolidinecarboxylic acids. It is commonly known as L-proline tert-butyl ester and is an ester derivative of the amino acid L-proline. 1-Pyrrolidinecarboxylic acid, 2-(hydroxyMethyl)-4,4-diMethyl-, 1,1-diMethylethyl ester, (2S)- is mainly used in organic synthesis and pharmaceutical research as a chiral building block for the synthesis of various pharmaceutical ingredients and biologically active compounds. Its unique structure and properties make it a valuable intermediate in the production of drugs and other fine chemicals.

Upstream product

• 144978-35-8 (S)-ethyl N-tert-butoxycarbonylpyroglutamate 
• 156088-46-9 (5S)-3,3-dimethyl-5-hydroxymethylpyrrolidin-2-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 212890-85-2 (S)-(+)-(4,4-dimethylpyrrolidin-2-yl)methan-1-ol 
• 1001353-87-2 (2S)-1-(tert-butoxycarbonyl)-4,4-dimethylpyrrolidine-2-carboxylic acid 
• 138423-86-6 Methyl (2S)-1-(tert-bytoxycarbonyl)-4,4-dimethylprolinate 
• 221637-35-0 (S)-ethyl 4,4-dimethyl-5-oxopyrrolidine-2-carboxylate 
• 158392-80-4 1-tert-butyl 2-ethyl (2S)4,4-dimethyl-5-oxopyrrolidine-1,2-dicarboxylate 

Downstream Products

• 184699-47-6 (S)-(-)-tert-butyl 4,4-dimethyl-2-[((4-methylphenyl)sulfonyloxy)methyl]pyrrolidinecarboxylate 
• 212890-84-1 (S)-2-[(Diphenylphosphanyl)-methyl]-4,4-dimethyl-pyrrolidine 
• 212890-87-4 (S)-(-)-tert-butyl 2-[(diphenylphosphino)methyl]-4,4-dimethylpyrrolidinecarboxylate 

Relevant articles and documents

MODULATORS OF HEMOGLOBIN FOR THE TREATMENT OF SICKLE CELL DISEASE

The present disclosure relates to compounds of the general formula (I) and pharmaceutical compositions containing them. The compounds are suitable as modulators of hemoglobin and thus useful in treating disorders mediated by hemoglobin such as sickle cell disease.

TETRACYCLIC INDOLE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION

Tetracyclic indole derivatives of formula (I), pharmaceutically acceptable salts and the pharmaceutical compositions thereof are provided, wherein A, A', G, R1, R15, U, V, V, W, W, X, X', Y, Y' are as defined in the invention. Use of these derivatives for treating hepatitis C virus (HCV) infection is also provided.

TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES

The present invention relates to novel Tetracyclic Indole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprisingat least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing HCV infection in a patient.